Adult Vaccine Market, Global Analysis By Disease (Influenza, Cervical Cancer, Zoster, MMR , Pneumonia, Meningitis, Hepatitis, Tap , Varicella & Travel & Miscellaneous Vaccine) & Companies
Adult Vaccine Market is projected to reach US$ 22 Billion by the year 2024. Vaccination can help prevent certain diseases in all the people. Nearly all countries across the globe have introduced a well-organized National immunization Programs in their vaccination schedule to overcome the outbreak of vaccine-preventable diseases. Several organizations such as Global Immunization Vision and Strategy (GIVS), WHO’s Global Vaccine Action Plan, The GAVI Alliance are putting their best to reduce the occurrence of vaccine-preventable diseases around the world which certainly is driving the adult vaccine market sturdily.
Rising prevalence of diseases, growing awareness among the people regarding vaccine-preventable diseases, increasing investments by companies to develop new vaccines and increasing governments and other healthcare authorities (Bill & Melinda Gates Foundation) funding for promoting immunization programs as well as for the developments & distribution of the vaccines are some other key factors which are anticipated to augment the growth of global adult vaccine during the forecast period.
Renub Research report titled “Adult Vaccine Market, Global Analysis By Disease [Influenza, Cervical Cancer, Zoster (Shingles), MMR (Measles, Mumps, and Rubella), Pneumonia, Meningitis, Hepatitis, Tap (Diphtheria, Tetanus, Pertussis), Varicella and Travel & Miscellaneous Vaccine], Companies (GlaxoSmithKline, Merck, Sanofi, Pfizer, & Others)” provides a complete analysis of Global Adults Vaccine Market.
By Disease - Pneumococcal Vaccine is likely to grow at noteworthy rate over the coming years
The report studies the market of the following vaccine: Influenza, Cervical Cancer, Zoster (Shingles), MMR (Measles, Mumps, and Rubella), Pneumonia, Meningitis, Hepatitis, Tap (Diphtheria, Tetanus, Pertussis), Varicella, and Travel & Miscellaneous Vaccine. Pneumococcal and Hepatitis together hold the significant market share in global adult vaccine market and is expected to continue so in the forecast period.
By End User – Global Adults Vaccine Market
The report studies the market by end user as Adults. Around the world, thousands of adults become seriously ill, get hospitalized and even die because of diseases that vaccines can help prevent. By getting vaccinated, one can help protect themselves from much of this needless suffering.
Almost 350 Million Adults get vaccinated by 2024
Due to the increasing prevalence of diseases and growing awareness regarding the vaccine-preventable diseases, it is estimated that by the year 2024, nearly 350 million adults get vaccinated; in order to protect themselves from diseases. Some of the vaccines which hold considerable share in terms of adult vaccination include Influenza, Hepatitis, HPV and Pneumonia vaccine.
Regional - Immunization Profile
The report also studies the Immunization profile around the world; By Disease - Measles, Mumps, Rubella, Japanese encephalitis, Tetanus, Pertussis, Yellow Fever. While By Regions, it studies Americas (AMR), Europe (EUR), Africa (AFR), Eastern Mediterranean (EMR), South-East Asia (SEAR), Western Pacific (WPR) and Global.
Company Analysis
GlaxoSmithKline, Merck, Sanofi, and Pfizer are some of the top companies that deal efficiently in vaccine business globally. These companies have been studied thoroughly in the report.
Global Adults Vaccine Market has been extensively studied from 3 major points:
1. Adult Vaccines (Disease wise) Market & Forecast
2. Number of Vaccinated Adults (Disease wise) & Forecast
3. Doses of Vaccines Administered in Adults(Disease wise) & Forecast
By Disease
Rising prevalence of diseases, growing awareness among the people regarding vaccine-preventable diseases, increasing investments by companies to develop new vaccines and increasing governments and other healthcare authorities (Bill & Melinda Gates Foundation) funding for promoting immunization programs as well as for the developments & distribution of the vaccines are some other key factors which are anticipated to augment the growth of global adult vaccine during the forecast period.
Renub Research report titled “Adult Vaccine Market, Global Analysis By Disease [Influenza, Cervical Cancer, Zoster (Shingles), MMR (Measles, Mumps, and Rubella), Pneumonia, Meningitis, Hepatitis, Tap (Diphtheria, Tetanus, Pertussis), Varicella and Travel & Miscellaneous Vaccine], Companies (GlaxoSmithKline, Merck, Sanofi, Pfizer, & Others)” provides a complete analysis of Global Adults Vaccine Market.
By Disease - Pneumococcal Vaccine is likely to grow at noteworthy rate over the coming years
The report studies the market of the following vaccine: Influenza, Cervical Cancer, Zoster (Shingles), MMR (Measles, Mumps, and Rubella), Pneumonia, Meningitis, Hepatitis, Tap (Diphtheria, Tetanus, Pertussis), Varicella, and Travel & Miscellaneous Vaccine. Pneumococcal and Hepatitis together hold the significant market share in global adult vaccine market and is expected to continue so in the forecast period.
By End User – Global Adults Vaccine Market
The report studies the market by end user as Adults. Around the world, thousands of adults become seriously ill, get hospitalized and even die because of diseases that vaccines can help prevent. By getting vaccinated, one can help protect themselves from much of this needless suffering.
Almost 350 Million Adults get vaccinated by 2024
Due to the increasing prevalence of diseases and growing awareness regarding the vaccine-preventable diseases, it is estimated that by the year 2024, nearly 350 million adults get vaccinated; in order to protect themselves from diseases. Some of the vaccines which hold considerable share in terms of adult vaccination include Influenza, Hepatitis, HPV and Pneumonia vaccine.
Regional - Immunization Profile
The report also studies the Immunization profile around the world; By Disease - Measles, Mumps, Rubella, Japanese encephalitis, Tetanus, Pertussis, Yellow Fever. While By Regions, it studies Americas (AMR), Europe (EUR), Africa (AFR), Eastern Mediterranean (EMR), South-East Asia (SEAR), Western Pacific (WPR) and Global.
Company Analysis
GlaxoSmithKline, Merck, Sanofi, and Pfizer are some of the top companies that deal efficiently in vaccine business globally. These companies have been studied thoroughly in the report.
Global Adults Vaccine Market has been extensively studied from 3 major points:
1. Adult Vaccines (Disease wise) Market & Forecast
2. Number of Vaccinated Adults (Disease wise) & Forecast
3. Doses of Vaccines Administered in Adults(Disease wise) & Forecast
By Disease
- Influenza
- Cervical Cancer
- Zoster (Shingles)
- MMR (Measles, Mumps, and Rubella)
- Pneumonia
- Meningitis
- Hepatitis
- Tap (Diphtheria, Tetanus, Pertussis)
- Varicella
- Travel & Miscellaneous Vaccine
- GlaxoSmithKline
- Merck
- Sanofi
- Pfizer
1. RESEARCH FINDINGS
2. ADULT VACCINES MARKET (2011 – 2024)
3. MARKET & NUMBERS SHARE - ADULT VACCINES
3.1 Adult Vaccine Market Share
3.2 Adult Vaccinated Population Share
3.3 Adult Doses of Vaccines Administered Share
3.4 Vaccine Companies Market Share
4. ADULT VACCINATED NUMBERS
5. ADULT DOSES OF VACCINES ADMINISTERED
6. DISEASE WISE – ADULT VACCINES MARKET (2011 – 2024)
6.1 Influenza
6.2 Cervical Cancer (HPV)
6.3 Zoster (Shingles)
6.4 MMR (Measles, Mumps, and Rubella Vaccine)
6.5 Pneumococcal
6.6 Meningococcal
6.7 Hepatitis
6.8 TdaP
6.9 Travel and Miscellaneous
6.10 Varicella
7. DISEASE WISE – NUMBERS OF VACCINATED ADULTS (2011 – 2024)
7.1 Influenza
7.2 Cervical Cancer (HPV)
7.3 Zoster (Shingles)
7.4 MMR
7.5 Pneumococcal
7.6 Meningococcal
7.7 Hepatitis
7.8 TdaP
7.9 Varicella
8. DISEASE WISE – DOSES OF VACCINES ADMINISTERED IN ADULTS (2011 – 2024)
8.1 Influenza
8.2 Cervical Cancer (HPV)
8.3 Zoster (Shingles)
8.4 MMR
8.5 Pneumococcal
8.6 Meningococcal
8.7 Hepatitis
8.8 TdaP
8.9 Varicella
9. DISEASE WISE - IMMUNIZATION PROFILE
9.1 Immunization Coverage (%) in Infants
9.2 Global Immunization Profile
9.3 By Geographic Region – Immunization Profile
9.3.1 Measles – Number of Reported Cases
9.3.2 Mumps – Number of Reported Cases
9.3.3 Rubella – Number of Reported Cases
9.3.4 Rubella (CRS) – Number of Reported Cases
9.3.5 Diphtheria – Number of Reported Cases
9.3.6 Tetanus (Neonatal) – Number of Reported Cases
9.3.7 Tetanus (Total) – Number of Reported Cases
9.3.8 Pertussis – Number of Reported Cases
9.3.9 Polio – Number of Reported Cases
9.3.10 Yellow Fever – Number of Reported Cases
9.3.11 Japanese encephalitis – Number of Reported Cases
10. VACCINES KEY PLAYERS SALES (2011 – 2024)
10.1 GlaxoSmithKline, plc.’s Vaccines Sales
10.2 Merck & Co. Vaccines Sales
10.3 Sanofi Pasteur’s Vaccines Sales
10.4 Pfizer, Inc.’s Vaccines Sales
10.5 Global – Other Companies Vaccines Sales
11. VACCINES – PRODUCTS AND PIPELINE
11.1 GSK Vaccine Product Pipeline
11.2 Merck Vaccine Product Pipeline
11.3 Sanofi Vaccine Product Pipeline
11.4 Pfizer Vaccine Product Pipeline
12. TOP MERGERS AND ACQUISITIONS IN THE VACCINE INDUSTRY
13. VACCINES AND REGULATOR’S INTERVENTIONS
13.1 Making and Meeting Standards of Quality and Safety
13.2 Vaccine Funding
14. VACCINE MARKET DRIVERS
14.1 Inclusion in National Immunization Schedule
14.2 Growing Immunization Coverage for HPV Vaccines
14.3 Increase in Prevalence of Infectious Diseases
14.4 Global Immunization Vision and Strategy (GIVS)
14.5 GAVI Model Fuelling Vaccine Manufacturers
14.5.1 The Partnership Model
14.5.2 The Business Model
14.6 Increasing Vaccine Availability in United States
14.7 The Vaccine Safety Data link Project
14.8 The Vaccine Injury Compensation Program
14.9 Transforming of Vaccine Technologies
14.10 Global Vaccine Action Plan by WHO (2011 - 2020)
14.11 Continuous Focus on Effective Communication Strategies
15. VACCINES MARKET CHALLENGES
15.1 Hurdles to Optimal use of Licensed Vaccines
15.1.1 Technical Obstacles
15.1.2 Economic Obstacles
15.1.3 Cultural Obstacles
15.2 Complexity of Vaccine Development & Approval System Thwarts Product Development
15.2.1 Legal Obstacles
15.2.2 General Technical Barriers
15.2.3 Economic Barriers
15.2.4 Regulatory Barriers
15.3 Shortening the Timeline for Vaccine Development
15.4 Refusal/Resistance to Vaccination
15.4.1 Vaccine Adverse Event Reporting System
15.5 Vaccine Shortages and Delays
15.6 Obstacles in Vaccine Research & Development
15.7 Barriers to New Entrants in the Vaccines Market
2. ADULT VACCINES MARKET (2011 – 2024)
3. MARKET & NUMBERS SHARE - ADULT VACCINES
3.1 Adult Vaccine Market Share
3.2 Adult Vaccinated Population Share
3.3 Adult Doses of Vaccines Administered Share
3.4 Vaccine Companies Market Share
4. ADULT VACCINATED NUMBERS
5. ADULT DOSES OF VACCINES ADMINISTERED
6. DISEASE WISE – ADULT VACCINES MARKET (2011 – 2024)
6.1 Influenza
6.2 Cervical Cancer (HPV)
6.3 Zoster (Shingles)
6.4 MMR (Measles, Mumps, and Rubella Vaccine)
6.5 Pneumococcal
6.6 Meningococcal
6.7 Hepatitis
6.8 TdaP
6.9 Travel and Miscellaneous
6.10 Varicella
7. DISEASE WISE – NUMBERS OF VACCINATED ADULTS (2011 – 2024)
7.1 Influenza
7.2 Cervical Cancer (HPV)
7.3 Zoster (Shingles)
7.4 MMR
7.5 Pneumococcal
7.6 Meningococcal
7.7 Hepatitis
7.8 TdaP
7.9 Varicella
8. DISEASE WISE – DOSES OF VACCINES ADMINISTERED IN ADULTS (2011 – 2024)
8.1 Influenza
8.2 Cervical Cancer (HPV)
8.3 Zoster (Shingles)
8.4 MMR
8.5 Pneumococcal
8.6 Meningococcal
8.7 Hepatitis
8.8 TdaP
8.9 Varicella
9. DISEASE WISE - IMMUNIZATION PROFILE
9.1 Immunization Coverage (%) in Infants
9.2 Global Immunization Profile
9.3 By Geographic Region – Immunization Profile
9.3.1 Measles – Number of Reported Cases
9.3.2 Mumps – Number of Reported Cases
9.3.3 Rubella – Number of Reported Cases
9.3.4 Rubella (CRS) – Number of Reported Cases
9.3.5 Diphtheria – Number of Reported Cases
9.3.6 Tetanus (Neonatal) – Number of Reported Cases
9.3.7 Tetanus (Total) – Number of Reported Cases
9.3.8 Pertussis – Number of Reported Cases
9.3.9 Polio – Number of Reported Cases
9.3.10 Yellow Fever – Number of Reported Cases
9.3.11 Japanese encephalitis – Number of Reported Cases
10. VACCINES KEY PLAYERS SALES (2011 – 2024)
10.1 GlaxoSmithKline, plc.’s Vaccines Sales
10.2 Merck & Co. Vaccines Sales
10.3 Sanofi Pasteur’s Vaccines Sales
10.4 Pfizer, Inc.’s Vaccines Sales
10.5 Global – Other Companies Vaccines Sales
11. VACCINES – PRODUCTS AND PIPELINE
11.1 GSK Vaccine Product Pipeline
11.2 Merck Vaccine Product Pipeline
11.3 Sanofi Vaccine Product Pipeline
11.4 Pfizer Vaccine Product Pipeline
12. TOP MERGERS AND ACQUISITIONS IN THE VACCINE INDUSTRY
13. VACCINES AND REGULATOR’S INTERVENTIONS
13.1 Making and Meeting Standards of Quality and Safety
13.2 Vaccine Funding
14. VACCINE MARKET DRIVERS
14.1 Inclusion in National Immunization Schedule
14.2 Growing Immunization Coverage for HPV Vaccines
14.3 Increase in Prevalence of Infectious Diseases
14.4 Global Immunization Vision and Strategy (GIVS)
14.5 GAVI Model Fuelling Vaccine Manufacturers
14.5.1 The Partnership Model
14.5.2 The Business Model
14.6 Increasing Vaccine Availability in United States
14.7 The Vaccine Safety Data link Project
14.8 The Vaccine Injury Compensation Program
14.9 Transforming of Vaccine Technologies
14.10 Global Vaccine Action Plan by WHO (2011 - 2020)
14.11 Continuous Focus on Effective Communication Strategies
15. VACCINES MARKET CHALLENGES
15.1 Hurdles to Optimal use of Licensed Vaccines
15.1.1 Technical Obstacles
15.1.2 Economic Obstacles
15.1.3 Cultural Obstacles
15.2 Complexity of Vaccine Development & Approval System Thwarts Product Development
15.2.1 Legal Obstacles
15.2.2 General Technical Barriers
15.2.3 Economic Barriers
15.2.4 Regulatory Barriers
15.3 Shortening the Timeline for Vaccine Development
15.4 Refusal/Resistance to Vaccination
15.4.1 Vaccine Adverse Event Reporting System
15.5 Vaccine Shortages and Delays
15.6 Obstacles in Vaccine Research & Development
15.7 Barriers to New Entrants in the Vaccines Market
LIST OF FIGURES
Figure 2-1: Global – Adult Vaccines Market (Billion US$), 2011 – 2017
Figure 2-2: Global – Forecast for Adult Vaccines Market (Billion US$), 2018 – 2024
Figure 3-1: Global – Adult Vaccines Market Share (Percent), 2011 - 2017
Figure 3-2: Global – Forecast for Adult Vaccines Market Share (Percent), 2018 - 2024
Figure 3-3: Global – Vaccinated Adult Share (Percent), 2011 - 2017
Figure 3-4: Global – Forecast for Vaccinated Adult Share (Percent), 2018 – 2024
Figure 3-5: Global – Doses of Vaccines Administered to Adult Share (Percent), 2011 - 2017
Figure 3-6: Global – Forecast for Doses of Vaccines Administered to Adult Share (Percent), 2018 - 2024
Figure 3-7: Global – Key Players Vaccines Market Share (Percent), 2011 - 2017
Figure 3-8: Global – Forecast for Key Players Vaccines Market Share (Percent), 2018 - 2024
Figure 4-1: Global – Number of Vaccinated Adult (Million), 2011 – 2017
Figure 4-2: Global – Forecast for Number of Vaccinated Adult (Million), 2018 – 2024
Figure 5-1: Global – Doses of Adult Vaccines Administered (Million), 2011 - 2017
Figure 5-2: Global – Forecast for Doses of Adult Vaccines Administered (Million), 2018 - 2024
Figure 6-1: Influenza – Adult Vaccines Market (Billion US$), 2011 - 2017
Figure 6-2: Influenza – Forecast for Adult Vaccines Market (Billion US$), 2018 – 2024
Figure 6-3: Cervical Cancer (HPV) – Vaccines Market (Billion US$), 2011 – 2017
Figure 6-4: Cervical Cancer (HPV) – Forecast for Vaccines Market (Billion US$), 2018 - 2024
Figure 6-5: Zoster (Shingles) – Vaccines Market (Billion US$), 2011 - 2017
Figure 6-6: Zoster (Shingles) – Forecast for Vaccines Market (Billion US$), 2018 - 2024
Figure 6-7: MMR – Adult Vaccines Market (Million US$), 2011 – 2017
Figure 6-8: MMR – Forecast for Adult Vaccines Market (Million US$), 2018 – 2024
Figure 6-9: Pneumococcal – Adult Vaccines Market (Billion US$), 2011 - 2017
Figure 6-10: Pneumococcal – Forecast for Adult Vaccines Market (Billion US$), 2018 – 2024
Figure 6-11: Areas with frequent epidemics of meningococcal meningitis
Figure 6-12: Meningococcal – Adult Vaccines Market (Million US$), 2011 – 2017
Figure 6-13: Meningococcal – Forecast for Adult Vaccines Market (Million US$), 2018 - 2024
Figure 6-14: Hepatitis – Adult Vaccines Market (Billion US$), 2011 - 2017
Figure 6-15: Hepatitis – Forecast for Adult Vaccines Market (Billion US$), 2018 - 2024
Figure 6-16: TdaP – Adult Vaccines Market (Million US$), 2011 - 2017
Figure 6-17: TdaP – Forecast for Adult Vaccines Market (Million US$), 2018 - 2024
Figure 6-18: Travel and Miscellaneous – Vaccines Market (Billion US$), 2011 - 2017
Figure 6-19: Travel and Miscellaneous – Forecast for Vaccines Market (Billion US$), 2018 - 2024
Figure 6-20: Varicella – Adult Vaccines Market (Million US$), 2011 - 2017
Figure 6-21: Varicella – Forecast for Adult Vaccines Market (Million US$), 2018 - 2024
Figure 7-1: Influenza – Number of Vaccinated Adults (Million), 2011 - 2017
Figure 7-2: Influenza – Forecast for Number of Vaccinated Adults (Million), 2018 - 2024
Figure 7-3: Cervical Cancer – Number of Vaccinated People (Million), 2011 - 2017
Figure 7-4: Cervical Cancer – Forecast for Number of Vaccinated People (Million), 2018 - 2024
Figure 7-5: Zoster (Shingles) – Number of Vaccinated People (Million), 2011 - 2017
Figure 7-6: Zoster (Shingles) – Forecast for Number of Vaccinated People (Million), 2018 - 2024
Figure 7-7: MMR – Number of Vaccinated Adults (Million), 2011 - 2017
Figure 7-8: MMR – Forecast for Number of Vaccinated Adults (Million), 2018 - 2024
Figure 7-9: Pneumococcal – Number of Vaccinated Adults (Million), 2011 - 2017
Figure 7-10: Pneumococcal – Forecast for Number of Vaccinated Adults (Million), 2018 - 2024
Figure 7-11: Meningococcal – Number of Vaccinated Adults (Million), 2011 - 2017
Figure 7-12: Meningococcal – Forecast for Number of Vaccinated Adults (Million), 2018 - 2024
Figure 7-13: Hepatitis – Number of Vaccinated Adults (Million), 2011 - 2017
Figure 7-14: Hepatitis – Forecast for Number of Adults Immunized (Thousand), 2018 - 2024
Figure 7-15: TdaP – Number of Vaccinated Adults (Million), 2011 - 2017
Figure 7-16: TdaP – Number of Vaccinated Adults (Million), 2018 - 2024
Figure 7-17: Varicella – Number of Vaccinated Adults (Million), 2011 - 2017
Figure 7-18: Varicella – Number of Vaccinated Adults (Million), 2018 - 2024
Figure 8-1: Influenza – Doses of Adult Vaccines Administered (Million), 2011 - 2017
Figure 8-2: Influenza – Forecast for Doses of Adult Vaccines Administered (Million), 2018 - 2024
Figure 8-3: Cervical Cancer (HPV) – Doses of Vaccines Administered (Million), 2011 - 2017
Figure 8-4: Cervical Cancer (HPV) – Forecast for Doses of Vaccines Administered (Million), 2018 - 2024
Figure 8-5: Zoster (Shingles) – Doses of Vaccines Administered (Million), 2011 - 2017
Figure 8-6: Zoster (Shingles) – Forecast for Doses of Vaccines Administered (Million), 2018 - 2024
Figure 8-7: MMR – Doses of Adult Vaccines Administered (Million), 2011 - 2017
Figure 8-8: MMR – Forecast for Doses of Adult Vaccines Administered (Million), 2018 - 2024
Figure 8-9: Pneumococcal – Doses of Adult Vaccines Administered (Million), 2011 - 2017
Figure 8-10: Pneumococcal – Forecast for Doses of Adult Vaccines Administered (Million), 2018 - 2024
Figure 8-11: Meningococcal – Doses of Adult Vaccines Administered (Million), 2011 - 2017
Figure 8-12: Meningococcal – Forecast for Doses of Adult Vaccines Administered (Million), 2018 - 2024
Figure 8-13: Hepatitis – Doses of Adult Vaccines Administered (Million), 2011 - 2017
Figure 8-14: Hepatitis – Forecast for Doses of Adult Vaccines Administered (Million), 2018 - 2024
Figure 8-15: TdaP – Doses of Adult Vaccines Administered (Million), 2011 - 2017
Figure 8-16: TdaP – Forecast for Doses of Adult Vaccines Administered (Million), 2018 - 2024
Figure 8-17: Varicella – Doses of Adult Vaccines Administered (Million), 2011 - 2017
Figure 8-18: Varicella – Forecast for Doses of Adult Vaccines Administered (Million), 2018 - 2024
Figure 10-1: Global - GlaxoSmithKline, plc.’s Vaccines Sales (Billion US$), 2011 - 2017
Figure 10-2: Global – Forecast for GlaxoSmithKline, plc.’s Vaccines Sales (Billion US$), 2018 - 2024
Figure 10-3: Global - Merck & Co. Vaccines Sales (Billion US$), 2011 - 2017
Figure 10-4: Global – Forecast for Merck & Co. Vaccines Sales (Billion US$), 2018 - 2024
Figure 10-5: Global - Sanofi Pasteur’s Vaccines Sales (Billion US$), 2011 - 2017
Figure 10-6: Global – Forecast for Sanofi Pasteur’s Vaccines Sales (Billion US$), 2018 - 2024
Figure 10-7: Global - Pfizer, Inc.’s Vaccines Sales (Billion US$), 2011 - 2017
Figure 10-8: Global – Forecast for Pfizer, Inc.’s Vaccines Sales (Billion US$), 2018 - 2024
Figure 10-9: Global – Other Companies Vaccines Sales (Billion US$), 2011 - 2017
Figure 10-10: Global – Forecast for Other Companies Vaccines Sales (Billion US$), 2018 - 2024
Figure 11-1: GSK Vaccine Product Pipeline
Figure 14-1: Countries with HPV Vaccination Program listed on their National Immunization Program (NIP) Schedule
Figure 14-2: Number of Cases of Diphtheria, Pertussis, Tetnaus & Measles by Major Region Worldwide, 2013
Figure 14-3: Vaccines Procured by UNICEF: Industrialized and Emerging Market Country Manufacturers
Figure 14-4: Vaccines procured by UNICEF: Industrialized and Emerging Market Country Manufacturers
Figure 14-5: US Retail Clinics Expected to Surge by 2017
Figure 2-1: Global – Adult Vaccines Market (Billion US$), 2011 – 2017
Figure 2-2: Global – Forecast for Adult Vaccines Market (Billion US$), 2018 – 2024
Figure 3-1: Global – Adult Vaccines Market Share (Percent), 2011 - 2017
Figure 3-2: Global – Forecast for Adult Vaccines Market Share (Percent), 2018 - 2024
Figure 3-3: Global – Vaccinated Adult Share (Percent), 2011 - 2017
Figure 3-4: Global – Forecast for Vaccinated Adult Share (Percent), 2018 – 2024
Figure 3-5: Global – Doses of Vaccines Administered to Adult Share (Percent), 2011 - 2017
Figure 3-6: Global – Forecast for Doses of Vaccines Administered to Adult Share (Percent), 2018 - 2024
Figure 3-7: Global – Key Players Vaccines Market Share (Percent), 2011 - 2017
Figure 3-8: Global – Forecast for Key Players Vaccines Market Share (Percent), 2018 - 2024
Figure 4-1: Global – Number of Vaccinated Adult (Million), 2011 – 2017
Figure 4-2: Global – Forecast for Number of Vaccinated Adult (Million), 2018 – 2024
Figure 5-1: Global – Doses of Adult Vaccines Administered (Million), 2011 - 2017
Figure 5-2: Global – Forecast for Doses of Adult Vaccines Administered (Million), 2018 - 2024
Figure 6-1: Influenza – Adult Vaccines Market (Billion US$), 2011 - 2017
Figure 6-2: Influenza – Forecast for Adult Vaccines Market (Billion US$), 2018 – 2024
Figure 6-3: Cervical Cancer (HPV) – Vaccines Market (Billion US$), 2011 – 2017
Figure 6-4: Cervical Cancer (HPV) – Forecast for Vaccines Market (Billion US$), 2018 - 2024
Figure 6-5: Zoster (Shingles) – Vaccines Market (Billion US$), 2011 - 2017
Figure 6-6: Zoster (Shingles) – Forecast for Vaccines Market (Billion US$), 2018 - 2024
Figure 6-7: MMR – Adult Vaccines Market (Million US$), 2011 – 2017
Figure 6-8: MMR – Forecast for Adult Vaccines Market (Million US$), 2018 – 2024
Figure 6-9: Pneumococcal – Adult Vaccines Market (Billion US$), 2011 - 2017
Figure 6-10: Pneumococcal – Forecast for Adult Vaccines Market (Billion US$), 2018 – 2024
Figure 6-11: Areas with frequent epidemics of meningococcal meningitis
Figure 6-12: Meningococcal – Adult Vaccines Market (Million US$), 2011 – 2017
Figure 6-13: Meningococcal – Forecast for Adult Vaccines Market (Million US$), 2018 - 2024
Figure 6-14: Hepatitis – Adult Vaccines Market (Billion US$), 2011 - 2017
Figure 6-15: Hepatitis – Forecast for Adult Vaccines Market (Billion US$), 2018 - 2024
Figure 6-16: TdaP – Adult Vaccines Market (Million US$), 2011 - 2017
Figure 6-17: TdaP – Forecast for Adult Vaccines Market (Million US$), 2018 - 2024
Figure 6-18: Travel and Miscellaneous – Vaccines Market (Billion US$), 2011 - 2017
Figure 6-19: Travel and Miscellaneous – Forecast for Vaccines Market (Billion US$), 2018 - 2024
Figure 6-20: Varicella – Adult Vaccines Market (Million US$), 2011 - 2017
Figure 6-21: Varicella – Forecast for Adult Vaccines Market (Million US$), 2018 - 2024
Figure 7-1: Influenza – Number of Vaccinated Adults (Million), 2011 - 2017
Figure 7-2: Influenza – Forecast for Number of Vaccinated Adults (Million), 2018 - 2024
Figure 7-3: Cervical Cancer – Number of Vaccinated People (Million), 2011 - 2017
Figure 7-4: Cervical Cancer – Forecast for Number of Vaccinated People (Million), 2018 - 2024
Figure 7-5: Zoster (Shingles) – Number of Vaccinated People (Million), 2011 - 2017
Figure 7-6: Zoster (Shingles) – Forecast for Number of Vaccinated People (Million), 2018 - 2024
Figure 7-7: MMR – Number of Vaccinated Adults (Million), 2011 - 2017
Figure 7-8: MMR – Forecast for Number of Vaccinated Adults (Million), 2018 - 2024
Figure 7-9: Pneumococcal – Number of Vaccinated Adults (Million), 2011 - 2017
Figure 7-10: Pneumococcal – Forecast for Number of Vaccinated Adults (Million), 2018 - 2024
Figure 7-11: Meningococcal – Number of Vaccinated Adults (Million), 2011 - 2017
Figure 7-12: Meningococcal – Forecast for Number of Vaccinated Adults (Million), 2018 - 2024
Figure 7-13: Hepatitis – Number of Vaccinated Adults (Million), 2011 - 2017
Figure 7-14: Hepatitis – Forecast for Number of Adults Immunized (Thousand), 2018 - 2024
Figure 7-15: TdaP – Number of Vaccinated Adults (Million), 2011 - 2017
Figure 7-16: TdaP – Number of Vaccinated Adults (Million), 2018 - 2024
Figure 7-17: Varicella – Number of Vaccinated Adults (Million), 2011 - 2017
Figure 7-18: Varicella – Number of Vaccinated Adults (Million), 2018 - 2024
Figure 8-1: Influenza – Doses of Adult Vaccines Administered (Million), 2011 - 2017
Figure 8-2: Influenza – Forecast for Doses of Adult Vaccines Administered (Million), 2018 - 2024
Figure 8-3: Cervical Cancer (HPV) – Doses of Vaccines Administered (Million), 2011 - 2017
Figure 8-4: Cervical Cancer (HPV) – Forecast for Doses of Vaccines Administered (Million), 2018 - 2024
Figure 8-5: Zoster (Shingles) – Doses of Vaccines Administered (Million), 2011 - 2017
Figure 8-6: Zoster (Shingles) – Forecast for Doses of Vaccines Administered (Million), 2018 - 2024
Figure 8-7: MMR – Doses of Adult Vaccines Administered (Million), 2011 - 2017
Figure 8-8: MMR – Forecast for Doses of Adult Vaccines Administered (Million), 2018 - 2024
Figure 8-9: Pneumococcal – Doses of Adult Vaccines Administered (Million), 2011 - 2017
Figure 8-10: Pneumococcal – Forecast for Doses of Adult Vaccines Administered (Million), 2018 - 2024
Figure 8-11: Meningococcal – Doses of Adult Vaccines Administered (Million), 2011 - 2017
Figure 8-12: Meningococcal – Forecast for Doses of Adult Vaccines Administered (Million), 2018 - 2024
Figure 8-13: Hepatitis – Doses of Adult Vaccines Administered (Million), 2011 - 2017
Figure 8-14: Hepatitis – Forecast for Doses of Adult Vaccines Administered (Million), 2018 - 2024
Figure 8-15: TdaP – Doses of Adult Vaccines Administered (Million), 2011 - 2017
Figure 8-16: TdaP – Forecast for Doses of Adult Vaccines Administered (Million), 2018 - 2024
Figure 8-17: Varicella – Doses of Adult Vaccines Administered (Million), 2011 - 2017
Figure 8-18: Varicella – Forecast for Doses of Adult Vaccines Administered (Million), 2018 - 2024
Figure 10-1: Global - GlaxoSmithKline, plc.’s Vaccines Sales (Billion US$), 2011 - 2017
Figure 10-2: Global – Forecast for GlaxoSmithKline, plc.’s Vaccines Sales (Billion US$), 2018 - 2024
Figure 10-3: Global - Merck & Co. Vaccines Sales (Billion US$), 2011 - 2017
Figure 10-4: Global – Forecast for Merck & Co. Vaccines Sales (Billion US$), 2018 - 2024
Figure 10-5: Global - Sanofi Pasteur’s Vaccines Sales (Billion US$), 2011 - 2017
Figure 10-6: Global – Forecast for Sanofi Pasteur’s Vaccines Sales (Billion US$), 2018 - 2024
Figure 10-7: Global - Pfizer, Inc.’s Vaccines Sales (Billion US$), 2011 - 2017
Figure 10-8: Global – Forecast for Pfizer, Inc.’s Vaccines Sales (Billion US$), 2018 - 2024
Figure 10-9: Global – Other Companies Vaccines Sales (Billion US$), 2011 - 2017
Figure 10-10: Global – Forecast for Other Companies Vaccines Sales (Billion US$), 2018 - 2024
Figure 11-1: GSK Vaccine Product Pipeline
Figure 14-1: Countries with HPV Vaccination Program listed on their National Immunization Program (NIP) Schedule
Figure 14-2: Number of Cases of Diphtheria, Pertussis, Tetnaus & Measles by Major Region Worldwide, 2013
Figure 14-3: Vaccines Procured by UNICEF: Industrialized and Emerging Market Country Manufacturers
Figure 14-4: Vaccines procured by UNICEF: Industrialized and Emerging Market Country Manufacturers
Figure 14-5: US Retail Clinics Expected to Surge by 2017
LIST OF TABLES
Table 2-1: Vaccine Recommendations
Table 2-2: Other Recommended Vaccines
Table 9-1: Worldwide Immunization Coverage (%) in Infants, 2005- 2010
Table 9-2: Worldwide Immunization Coverage (%) in Infants, 2011- 2016
Table 9-3: Vaccines – Number of Reported Cases, 2011 – 2017
Table 9-4: Measles – Number of Reported Cases, 2001 – 2016
Table 9-5: Mumps – Number of Reported Cases, 2001 - 2016
Table 9-6: Rubella – Number of Reported Cases, 2001 - 2016
Table 9-7: Rubella (CRS) – Number of Reported Cases, 2001 - 2016
Table 9-8: Diphtheria – Number of Reported Cases, 2001 - 2016
Table 9-9: Tetanus (Neonatal) – Number of Reported Cases, 2001 – 2016
Table 9-10: Tetanus (Total) – Number of Reported Cases, 2001 - 2016
Table 9-11: Pertussis – Number of Reported Cases, 2001 - 2016
Table 9-12: Polio – Number of Reported Cases, 2001 - 2016
Table 9-13: Yellow Fever – Number of Reported Cases, 2001 - 2016
Table 9-14: Japanese Encephalitis – Number of Reported Cases Reported, 2006 - 2016
Table 11-1: Merck Vaccine Product Pipeline
Table 11-2: Sanofi Vaccine Product Pipeline
Table 11-3: Pfizer Vaccine Product Pipeline
Table 12-1: Vaccine Mergers & Acquisitions
Table 14-1: United States Immunization Schedule
Table 14-2: Afghanistan Immunization Schedule
Table 14-3: Norway Immunization Schedule
Table 14-4: India Immunization Schedule
Table 14-5: Vietnam Immunization Schedule
Table 14-6: Worldwide – Total Future Deaths Averted through Vaccination (Million), 2011 – 2020
Table 14-7: Goal-Level Indicators, 2015 & 2020
Table 14-8: Improvement Strategies or Requirements – the Joint Commission and the Project’s Collaborating Organizations
Table 2-1: Vaccine Recommendations
Table 2-2: Other Recommended Vaccines
Table 9-1: Worldwide Immunization Coverage (%) in Infants, 2005- 2010
Table 9-2: Worldwide Immunization Coverage (%) in Infants, 2011- 2016
Table 9-3: Vaccines – Number of Reported Cases, 2011 – 2017
Table 9-4: Measles – Number of Reported Cases, 2001 – 2016
Table 9-5: Mumps – Number of Reported Cases, 2001 - 2016
Table 9-6: Rubella – Number of Reported Cases, 2001 - 2016
Table 9-7: Rubella (CRS) – Number of Reported Cases, 2001 - 2016
Table 9-8: Diphtheria – Number of Reported Cases, 2001 - 2016
Table 9-9: Tetanus (Neonatal) – Number of Reported Cases, 2001 – 2016
Table 9-10: Tetanus (Total) – Number of Reported Cases, 2001 - 2016
Table 9-11: Pertussis – Number of Reported Cases, 2001 - 2016
Table 9-12: Polio – Number of Reported Cases, 2001 - 2016
Table 9-13: Yellow Fever – Number of Reported Cases, 2001 - 2016
Table 9-14: Japanese Encephalitis – Number of Reported Cases Reported, 2006 - 2016
Table 11-1: Merck Vaccine Product Pipeline
Table 11-2: Sanofi Vaccine Product Pipeline
Table 11-3: Pfizer Vaccine Product Pipeline
Table 12-1: Vaccine Mergers & Acquisitions
Table 14-1: United States Immunization Schedule
Table 14-2: Afghanistan Immunization Schedule
Table 14-3: Norway Immunization Schedule
Table 14-4: India Immunization Schedule
Table 14-5: Vietnam Immunization Schedule
Table 14-6: Worldwide – Total Future Deaths Averted through Vaccination (Million), 2011 – 2020
Table 14-7: Goal-Level Indicators, 2015 & 2020
Table 14-8: Improvement Strategies or Requirements – the Joint Commission and the Project’s Collaborating Organizations
